Results 31 to 40 of about 219,590 (352)

Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer

New England Journal of Medicine, 2018
Background Standard first‐line therapy for metastatic, squamous non–small‐cell lung cancer (NSCLC) is platinum‐based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD‐L1] expression on ≥50% of tumor cells).
L. Paz-Ares, A. Luft, D. Vicente, A. Tafreshi, M. Gümüş, J. Mazières, B. Hermes, F. Senler, T. Csőszi, A. Fülöp, J. Rodríguez-Cid, Jonathan Wilson, S. Sugawara, T. Kato, K. Lee, Ying Cheng, S. Novello, B. Halmos, Xiaodong Li, G. Lubiniecki, B. Piperdi, D. Kowalski   +21 more
semanticscholar   +1 more source

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

New England Journal of Medicine, 2023
BACKGROUND Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage
S. Patel, M. Othus, Yuanbin Chen, G. Wright, K. Yost, John R Hyngstrom, S. Hu-Lieskovan, C. Lao, L. Fecher, T. Truong, Jennifer Eisenstein, S. Chandra, J. A. Sosman, K. Kendra, Richard C Wu, C. Devoe, G. Deutsch, A. Hegde, M. Khalil, Ankit Mangla, A. Reese, M. Ross, A. Poklepovic, G. Phan, A. Onitilo, Demet Yaşar, Benjamin Powers, G. Doolittle, G. In, Niels Kokot, G. Gibney, M. Atkins, M. Shaheen, J. Warneke, A. Ikeguchi, J. E. Najera, B. Chmielowski, J. Crompton, J. Floyd, E. Hsueh, K. Margolin, W. Chow, K. Grossmann, E. Dietrich, V. Prieto, M. Lowe, E. Buchbinder, John M. Kirkwood, L. Korde, J. Moon, E. Sharon, V. Sondak, A. Ribas   +52 more
semanticscholar   +1 more source

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Journal of Clinical Oncology, 2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
S. Novello, D. Kowalski, A. Luft, M. Gümüş, D. Vicente, J. Mazières, J. Rodríguez-Cid, A. Tafreshi, Ying Cheng, K. Lee, A. Golf, S. Sugawara, A. Robinson, B. Halmos, E. Jensen, P. Schwarzenberger, M. Pietanza, L. Paz-Ares   +17 more
semanticscholar   +1 more source

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Frontiers in Oncology, 2023
BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil ...
Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, Gleicy M. Hair   +6 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

New England Journal of Medicine, 2020
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy.
T. André, K. Shiu, Tae Won Kim, B. V. Jensen, L. Jensen, C. Punt, Denis Smith, R. García-Carbonero, M. Benavides, P. Gibbs, C. de la Fouchardière, F. Rivera, E. Élez, J. Bendell, D. Le, T. Yoshino, E. Van Cutsem, Ping Yang, M. Farooqui, P. Marinello, L. Diaz   +20 more
semanticscholar   +1 more source

Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation

Respiratory Medicine Case Reports, 2019
A 66-year-old Japanese man with recurrent adenocarcinoma of the lung p-stage IIIA (pT2bN2M0; version 8) on pembrolizumab was present with gradually worsening dyspnea.
Ryo Ueno, Masahiro Nemoto, Wataru Uegami, Junya Fukuoka, Masafumi Misawa   +4 more
doaj   +1 more source

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
J. Cortés, H. Rugo, D. Cescon, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, J. Peréz-García, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Zifang Guo, Xuan Zhou, V. Karantza, W. Pan, P. Schmid   +18 more
semanticscholar   +1 more source